InvestorsHub Logo
Followers 831
Posts 120016
Boards Moderated 17
Alias Born 09/05/2002

Re: alternatepatel post# 12061

Monday, 06/23/2014 2:16:22 PM

Monday, June 23, 2014 2:16:22 PM

Post# of 20689
I don’t have a one-year target price per se. The share price in one year is highly dependent on the FDA’s actions on NVS/MNTA’s Copaxone ANDA, MYL’s Copaxone ANDA, and (to a lesser degree) the Copaxone patent case.

Note: I do think the market is undervaluing MNTA’s non-Copaxone assets—see #msg-99790077 and #msg-100189277.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”